Recent scientific evidence in the contribution of ultraviolet light and genetic mutation in squamous cell carcinoma (SCC) pathogenesis sheds new light on the impact of the field cancer model. The session, “Field Cancerization and Multiple SCC: New Molecular Insights and Evidence-Based Clinical Management” (FOC U037) from 7:30 to 8:30 a.m. Saturday in Room 209, exposes attendees to current thinking.
Sean Christensen, MD, PhD, leads the session, which is designed for general dermatologists and dermatologic surgeons. Dr. Christensen takes attendees through an overview of the common development of multiple SCCs within areas of actinic damage and the field cancerization paradigm. Specifically, Dr. Christensen will lead a discussion on topical and systemic field treatments, as well as the evidence suggesting that these treatments could possibly prevent the development of SCC.
Session content will instruct attendees on how to identify patients at risk for the development of multiple SCC pathogenesis, recognize the impact of ultraviolet light and genetic mutations to that development within a field of actinic damage, and select and prescribe appropriate field treatment to decrease the incidence and progression of SCC for individual patients.
Attendees can earn 1 CME credit for the session; no tuition or ticket is required for the session.